CalciMedica Inc
Research CalciMedica Inc (CALC) on Bullrun: market cap USD 18.07M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCALC
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 18.07M
- Financial periodQ1 2026
- RevenueUSD 0
- Net incomeUSD 4.98M
- Free cash flow-USD 4.86M
Valuation Snapshot
latest market cap is USD 18.07M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 29.56M | -USD 21.21M | n/a | -1.97 | USD 11.52M | USD 9.70M | -USD 6.64M |
| FY2024 | USD 0 | -USD 13.70M | -USD 21.15M | n/a | -1.22 | USD 7.94M | n/a | USD 14.41M |
| FY2023 | n/a | -USD 34.36M | -USD 25.81M | n/a | -7.66 | USD 5.53M | n/a | USD 8.16M |
| FY2022 | n/a | -USD 7.82M | -USD 11.76M | n/a | -111.16 | USD 1.33M | USD 5.16M | -USD 71.30M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 18.07M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 101.73M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 47.73M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 16.26M | n/a | n/a | n/a |
About CalciMedica Inc
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is CalciMedica Inc's market cap?
CalciMedica Inc's market capitalization is USD 18.07M.
What does CalciMedica Inc do?
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.